The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
CNBC's Becky Quick reports on the latest news.
The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...
The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by ...
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will ...
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
Credit: da-kuk via Getty Images. Vertex Pharmaceuticals and Orna Therapeutics have announced a three-year collaboration to develop next-generation gene therapies for sickle cell disease (SCD) and ...
The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.
More than 60 WBUR listeners and readers shared their stories — and photos — with us to collectively commemorate, rage and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback